Khor Yet H, Moor Catharina C, Merkt Wolfgang, Buschulte Katharina, Zheng Boyang, Müller Veronika, Kreuter Michael
Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Australia
Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia.
Eur Respir Rev. 2025 Jul 23;34(177). doi: 10.1183/16000617.0046-2025. Print 2025 Jul.
Connective tissue disease-associated interstitial lung disease is one of the most common subtypes of interstitial lung disease, which is a leading cause of morbidity and mortality in patients with these systemic autoimmune rheumatic diseases. A spectrum of disease trajectories exists within individual and across different connective tissue diseases. In individuals with connective tissue diseases who are at risk or at the early asymptomatic stage with interstitial lung changes, we have potential windows of opportunity for interventions to prevent the development of or progression to interstitial lung disease. In this perspective, we use systemic sclerosis and rheumatoid arthritis as sample cases to discuss emerging knowledge on disease pathogenesis, as well as to apply the preventative medicine concept for pharmacotherapeutic approaches at different disease stages of connective tissue disease-associated interstitial lung disease.
结缔组织病相关间质性肺疾病是间质性肺疾病最常见的亚型之一，是这些系统性自身免疫性风湿性疾病患者发病和死亡的主要原因。个体内部以及不同结缔组织病之间存在一系列疾病轨迹。在有患间质性肺疾病风险或处于早期无症状阶段且有间质性肺改变的结缔组织病患者中，我们有干预的潜在机会窗口，以预防间质性肺疾病的发生或进展。从这个角度出发，我们以系统性硬化症和类风湿关节炎为例，讨论疾病发病机制的新知识，并将预防医学概念应用于结缔组织病相关间质性肺疾病不同疾病阶段的药物治疗方法。
